Navigation Links
Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
Date:4/28/2009

on (DKK 4 million). The increase primarily derived from increase in commercial activities on IMVAMUNE(R).

Administrative costs totalled DKK 23 million (DKK 17 million).

Income before tax was a deficit of DKK 83 million (deficit of DKK 62 million).

Net result was a deficit of DKK 66 million (deficit of DKK 50 million).

As of 31 March 2009 the Group's net free liquidity was DKK 627 million (DKK 971 million). Year to date cash flow from operations is negative with DKK -132 million (DKK -67 million). Cash flow from investment activities is DKK 33 million (DKK 127 million) and cash flow from financing activities is DKK -4 million (DKK -4 million). The net changes in cash and cash equivalents is negative with DKK -169 million (DKK +57 million) year to date.

After the close of the first quarter, the company decided to reduce the outstanding foreign exchange contracts. The remaining foreign exchange contracts of USD 46 million cover the expected USD income from the RFP-3 contract in 2009. The reduction in the outstanding foreign exchange contracts has been executed in order to eliminate the adverse effect on the liquidity a rise in USD will have.

The Group's equity as of 31 March 2009 was DKK 893 million (DKK 1,226 million.). The decrease flows from retained earnings.

Financial expectations

Bavarian Nordic maintains its expectations for the financial result for 2009. Thus, the company expects revenue in the region of DKK 375 million, and a pre-tax loss in the region of DKK 225 million. Revenue will primarily be generated from the delivery of IMVAMUNE(R) to the United States under the RFP-3 contract and billing of the continuation of the RFP-2 contract and contracts for smallpox vaccines already entered with other countries.

Forward-looking statements

This announcement includes "forward-looking statements" that involve
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... This is a ... provides a basic overview of the industry including definitions, classifications, applications and industry ... development trends, competitive landscape analysis, and key regions development status. Development policies and ...
(Date:7/27/2015)... --  Inocucor Technologies Inc ., the agriculture biotech ... has received a notice of allowance from the ... application to protect Inocucor consortia and unique microbial ... on farms and in greenhouses. This ... consortium and its fermentation byproducts, which are the ...
(Date:7/27/2015)... Texas , July 27, 2015 ... Market by Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, ... , Europe , Asia-Pacific ... to 2019", The global biopreservation media market was valued at ... around $571.5 million by 2019, at a CAGR of 18.2% ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, Inc. ... 8,000 clinics have submitted over 100,000 specimens to IDEXX ... just the first 10 days since the breakthrough kidney ... (CKD) is a leading cause of suffering and death ... specimens are consistent with generally accepted kidney disease prevalence ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a ... raw materials,for use in pharmaceutical, nutraceutical and food ... for the three and six month periods,ended June ... 2008, sales of our products increased,substantially. Revenue received ...
... 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... (Amex: CSY ), a,leading fully integrated ... the People,s Republic of China ("PRC"), today,announced ... for the treatment,and prevention of rheumatic disease., ...
... Inc. (Nasdaq: ADLS ), a biopharmaceutical company ... drugs in the,therapeutic areas of infection, cancer and ... second quarter ended June 30, 2008., (Logo: ... the three months was $3.4 million or ($0.09) ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 3Advanced Life Sciences Announces Second Quarter 2008 Financial Results 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 3Advanced Life Sciences Announces Second Quarter 2008 Financial Results 4Advanced Life Sciences Announces Second Quarter 2008 Financial Results 5Advanced Life Sciences Announces Second Quarter 2008 Financial Results 6Advanced Life Sciences Announces Second Quarter 2008 Financial Results 7Advanced Life Sciences Announces Second Quarter 2008 Financial Results 8Advanced Life Sciences Announces Second Quarter 2008 Financial Results 9Advanced Life Sciences Announces Second Quarter 2008 Financial Results 10
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... 2008. A scientific project funded by the BBVA Foundation and ... Research (CSIC) explored around 100 kilometers of practically uncharted Atlantic ... between the years 2006 and 2007. In the course of ... new hope for the survival of the leatherback turtle. This ...
... an animal model of multiple sclerosis (MS), neuroradiologists and ... have been able to visualize inflammatory tissue damage, most ... the aid of a new contrast medium, Gadofluorine M, ... results in the online edition of the renowned medical ...
... the United States die every year from uncontrolled infections ... are pushing the boundaries of molecular science to find ... simple measure of an immune system protein within 24 ... shock can predict survival in children, yielding a powerful ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3
... The CellSensor CRE-bla HEK 293T cell ... control of the cAMP response element (CRE). ... construct was transduced into HEK 293T cells ... to isolate clones responsive to forskolin stimulation ...
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Request Info...
Biology Products: